Intra-articular injection of adipose-derived stromal vascular fraction in osteoarthritis of the temporomandibular joint - SVF injection in the TMJ

niversitair Medisch Centrum Groningen0 个研究点目标入组 40 人开始时间: 待定最近更新: 2024年4月9日

适应症

试验速览

暂无简介。

•* Age between 18-70 years
•* Chronic nociceptive pain in the TMJ region, aggravated by protrusion, maximal
•mouth opening, lateral excursions and/or chewing of at least 2 months
•* Wilkes stages III or IV (internal derangement)
•* Limited maximal interincisal opening (< 35 mm and > 15 mm)
•* Pain still present after two weeks of a NSAID (i.e. ibuprofen 600 mg three
•times daily, or diclophenac 50 mg 3td, or napoxen 500 mg 2 td)
•* Pain disappears after diagnostic intra-articular injection

•* Edentulous (no dentition)
•* Previous treatments acting on cartilage or bone metabolism (eg, oral or
•intravenous bisphosphonates <1 year previously, strontium ranelate or
•teriparatide or raloxifene <7 days prior to selection, and oral glucosamine
•*1500 mg/day and chondroitin sulphate <3 months previously)
•* Concurrent use of anti-inflammatory medication, steroids, muscle relaxants or
•antidepressants
•* Previous TMJ traumas and fractures
•* Previous TMJ surgeries, previous intra-articular injections < 1 year before
•* Bilateral severe TMJ derangements
•* Bony or fibrotic ankylosis of the TMJ
•* Known history of diabetes mellitus type 1 or 2
•* Known history of HIV
•* Serious systemic diseases, rheumatic disease or infectious/inflammatory
•diseases affecting the skin of the area of the TMJ
•* Pregnancy
•* Coagulation disorders
•* BMI <15

发起方